[Comparison of therapeutic peptides targeting pancreatic cancer]
Gábor Mezõ1, Levente Dókus2, Gitta Schlosser1
1Eötvös Loránd Tudományegyetem, Magyar Tudományos Akadémia, MTA-ELTE Peptidkémiai Kutatócsoport, Budapest, Hungary. gmezo@caesar.elte.hu.
Abstract:
Despite the small number of cases, pancreatic cancer is one of the biggest challenges in tumor therapy as its treatment is not yet resolved and the expected 5-year survival rate is only 5%. Therefore, innovative solutions for pancreatic cancer are of great importance. Targeted tumor therapy might provide new possibilities in this field. In our research, we focused on finding peptide-based homing molecules and modified their structure to achieve better targeting properties. We compared several peptides that efficiently recognize receptors that are specific for or overexpressed by pancreatic cancer cells. Their structure-effect relationship was determined that can be useful during drug designing in the future. The antitumor effect of Dau=Aoa-GFLG-K(Dau=Aoa) SKAAKN-OH conjugate, which turned out to be the most efficient one during in vitro studies, were analyzed in vivo in female SCID mice. The obtained 30% inhibition, beside the low toxic side effects, might be a good starting point to develop further, more powerful conjugates.
Insights
Developing novel peptide-based therapies for pancreatic cancer is crucial due to its poor prognosis. This study identified a promising conjugate with significant antitumor effects and low toxicity in preclinical models.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Pancreatic cancer presents a significant therapeutic challenge with a low 5-year survival rate.
- Existing treatments are insufficient, highlighting the need for innovative therapeutic strategies.
- Targeted tumor therapy offers potential new avenues for pancreatic cancer treatment.
Purpose of the Study:
- To identify and optimize peptide-based homing molecules for pancreatic cancer targeting.
- To investigate the structure-activity relationship of these peptides for improved drug design.
- To evaluate the in vivo efficacy and toxicity of a lead peptide conjugate.
Main Methods:
- Screening and comparison of various peptides for recognition of pancreatic cancer-specific receptors.
- Structural modification of peptides to enhance targeting capabilities.
- In vitro and in vivo evaluation of the most effective peptide conjugate (Dau=Aoa-GFLG-K(Dau=Aoa) SKAAKN-OH) in SCID mice models.
Main Results:
- Several peptides demonstrated efficient recognition of pancreatic cancer cell-specific receptors.
- The Dau=Aoa-GFLG-K(Dau=Aoa) SKAAKN-OH conjugate showed significant antitumor activity in vitro.
- In vivo studies in SCID mice resulted in 30% tumor inhibition with minimal toxic side effects.
Conclusions:
- Peptide-based homing molecules can be effectively designed for targeted pancreatic cancer therapy.
- The evaluated conjugate represents a promising lead compound for further development.
- These findings provide a foundation for creating more potent peptide conjugates for pancreatic cancer treatment.
More Related Videos
07:08Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
Published on: February 2, 2024
07:32Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library
Published on: September 30, 2019
